New and emerging therapies in the treatment of blistering diseases (Q33811528)

29 July 2017

1 reference

title

New and emerging therapies in the treatment of blistering diseases (English)

1 reference

29 July 2017

Korman NJ

1 reference

29 July 2017

publication date

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

127-37, ix-x

1 reference

Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Generalized pruritus as the presenting feature of buUous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Dapsone as initial treatment in superficial pemphigus. Report of nine cases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Treatment of ocular cicatricial pemphigoid with intravenous gammaglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Bullous pemphigoid treated with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Paraneoplastic pemphigus: a report of three cases including one long-term survivor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Interferon alfa for linear IgA bullous dermatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Linear IgA bullous dermatosis of adults

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Treatment of epidermolysis bullosa acquisita with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Clearing of epidermolysis bullosa acquisita with cyclosporine.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Colchicine for epidermolysis bullosa acquisita

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Topical cyclosporine for oral bullous disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Mycophenolate is effective in the treatment of pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Pulse intravenous cyclophosphamide therapy in pemphigus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Immunosuppressive therapy for progressive ocular cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Epidermolysis bullosa acquisita: clinical response to plasma exchange therapy and circulating anti-basement membrane zone antibody titer

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Differentiating Anti-Lamina Lucida and Anti-Sublamina Densa Anti-BMZ Antibodies by Indirect Immunofluorescence on 1.0 M Sodium Chloride-Separated Skin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Controlled study of plasma exchange in pemphigus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Clinical, histological and immunological studies in 50 patients with bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Pure ocular cicatricial pemphigoid. A distinct immunopathologic subset of cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Envoplakin and Periplakin are Components of the Paraneoplastic Pemphigus Antigen Complex

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Immune-mediated subepithelial blistering diseases of the mucous membranes. Improving the detection of circulating autoantibodies by the use of concentrated serum samples

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Bullous pemphigoid successfully controlled by tetracycline and nicotinamide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Clearing of epidermolysis bullosa acquisita with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Cyclosporine consensus conference: with emphasis on the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Oral insertable prosthetic device as an aid in treating oral ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

1 reference

7 January 2021

Pemphigus and pemphigoid. A review of the advances made since 1964.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

The use of chlorambucil in the treatment of bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Successful therapy for bullous pemphigoid with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Cicatricial pemphigoid successfully treated with pulse intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Treatment of pemphigus with gold

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Low-dose methotrexate treatment in elderly patients with bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Linear IgA bullous dermatosis: successful treatment with tetracycline and nicotinamide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Minimizing cicatricial pemphigoid orodynia with minocycline

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Pemphigus in remission: value of negative direct immunofluorescence in management

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Treatment of chronic bullous dermatosis of childhood with oral dicloxacillin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

The new pemphigus variants

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Plasma exchange in bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Paraneoplastic pemphigus in a child with a T-cell lymphoblastic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Immunoapheresis in paraneoplastic pemphigus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

High-dose methylprednisolone in the treatment of bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Identification of a basement membrane zone antigen reactive with circulating IgA antibody in ocular cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Treatment in bullous diseases with corticosteroid drugs and corticotrophin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Paraneoplastic pemphigus: a case with high titer of circulating anti-basement membrane zone autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Effects of cyclosporin on bullous pemphigoid and pemphigus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Cicatricial pemphigoid treated with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Dapsone as first line therapy for bullous pemphigoid.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Cicatrizing conjunctivitis as a predominant manifestation of linear IgA bullous dermatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

The 97kDa Linear IgA Bullous Disease Antigen Is Identical to a Portion of the Extracellular Domain of the 180kDa Bullous Pemphigoid Antigen, BPAg2

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970153-4

7 January 2021

10.1016/S0733-8635(05)70153-4

Identifiers

DOI

1 reference

29 July 2017

1 reference